GEN Exclusives

More »

GEN Exclusives

More »
Dec 30, 2011

2011 IPO Window for Biotechs Lets Through Fewer Companies

Just 13 firms went public compared to 16 in 2010, but discounts were smaller.

2011 IPO Window for Biotechs Lets Through Fewer Companies

Due to market volatility, more firms may go the M&A route rather than flocking to public markets. [© Lane Erickson - Fotolia.com]


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?